SEC Form 4 · accession 0001213900-26-075144

InMed Pharmaceuticals Inc. · INM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

Vivo Opportunity, LLC

10% Owner

Vivo Opportunity Cayman Fund, L.P.

10% Owner

Vivo Opportunity Cayman, LLC

10% Owner

Vivo Opportunity Fund Holdings, L.P.

10% Owner

Period of report

Jun 30, 2026

Accepted (ET)

Jul 2, 2026 · 7:02 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001728328

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Shares^F3,F1	Jun 30, 2026	P	545	$1.54	A	718,989	I	By Vivo Opportunity Fund Holdings, L.P.
Common Shares^F3,F2	Jun 30, 2026	P	55	$1.54	A	72,590	I	By Vivo Opportunity Cayman Fund, L.P.
Common Shares^F4,F1	Jul 1, 2026	P	3,946	$1.55	A	722,935	I	By Vivo Opportunity Fund Holdings, L.P.
Common Shares^F4,F2	Jul 1, 2026	P	398	$1.55	A	72,988	I	By Vivo Opportunity Cayman Fund, L.P.
Common Shares^F5,F1	Jul 2, 2026	P	1,460	$1.55	A	724,395	I	By Vivo Opportunity Fund Holdings, L.P.
Common Shares^F5,F2	Jul 2, 2026	P	147	$1.55	A	73,135	I	By Vivo Opportunity Cayman Fund, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F3The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.
F5The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4.